Position in EXEL
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$694,989
+$4,141 QoQ
Shares Held
16,204
+2.8% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
5 quarters on record
Voting authority
Sole 23.13009133547272.ToString("F0")%
Shared 0.ToString("F0")%
None 76.86990866452727.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Chicago Partners Investment Group LLC holds $9,972,920 across 37 Biotechnology names. EXEL ranks #5 (7.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,001 | $1,546,052 | |
| 2 | INCY |
Incyte Corp
|
8,174 | $769,336 | |
| 3 | TSHA |
Taysha Gene Therapies, Inc.
|
170,751 | $763,256 | |
| 4 | ASND |
Ascendis Pharma A/S
|
3,054 | $698,541 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
16,204 | $694,989 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
12,183 | $688,217 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
2,861 | $540,872 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,170 | $522,451 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $694,989 | 16,204 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $690,848 | 15,762 | Shares | Sole | 2026-01-28 | |
| 2025-09-30 | $370,337 | 8,967 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $321,651 | 7,297 | Shares | Sole | 2025-07-29 | |
| 2024-12-31 | $238,294 | 7,156 | Shares | Sole | 2025-01-24 | |
| No filing history on record for this holder in this stock. | ||||||